Previous 10 | Next 10 |
Clinical stage biopharmaceutical company Checkmate Pharmaceuticals (CMPI) announces appointment of former Akcea Therapeutics executive Robert Dolski as its Chief Financial Officer.Dolski has more than 20 years of diversified management experience as a life sciences financial ex...
Checkmate Pharmaceuticals ([[CMPI]] +4.2%) has entered into a clinical collaboration agreement with Bristol Myers Squibb ([[BMY]] +0.4%) to evaluate the combination of former's CMP-001, a Toll-like receptor 9 agonist, and later's Opdivo (nivolumab), a PD-1 blocking antibody.The companies will...
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals , Inc. (NASDAQ: CMPI) (“Checkmate Pharmaceuticals”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system ...
Checkmate Pharmaceuticals (CMPI): Q3 Net loss of $9.83M.Cash and cash equivalents of $137.34M.Press Release For further details see: Checkmate Pharmaceuticals reports Q3 results
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals , Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, to...
CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma in ongoing trial Encouraging new data on pathological responses and 1-year RFS with neoadjuvant CMP-001 and nivolumab in resectable Stage III ...
Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals , Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today ...
Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to much of a surprise to investors, as Iovance's TIL therapy carries a complex manufacturing and ...
CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma Encouraging new data on pathological responses and 1-year RFS with neoadjuvant CMP-001 and nivolumab in resectable Stage III melanoma CAMBRIDGE, Mass.,...
News, Short Squeeze, Breakout and More Instantly...
Checkmate Pharmaceuticals Inc. Company Name:
CMPI Stock Symbol:
NASDAQ Market:
Checkmate Pharmaceuticals Inc. Website:
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” ...
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat c...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today an...